Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies

20 Oct 2021

Abstract excerpt

Polyglutamine (polyQ) ataxias are a heterogenous group of neurological disorders all caused by an expanded CAG trinucleotide repeat located in the coding region of each unique causative gene. To date, polyQ ataxias encompass six disorders: spinocerebellar ataxia types 1, 2, 3, 6, 7, and 17 and account for a larger group of disorders simply known as polyglutamine disorders, which also includes Huntington's...

Source

Identifiers

PMID: 34829728
DOI: 10.3390/biomedicines9111499

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense TherapiesPMID 34829728Read ↗

Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disordersSemantic proximity Read ↗

Polyglutamine (PolyQ) Diseases: Genetics to TreatmentsSemantic proximity Read ↗

Spinocerebellar ataxias caused by polyglutamine expansions: a review of therapeutic strategies.Semantic proximity Read ↗

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of NeurodegenerationSemantic proximity Read ↗

Recent advances in understanding dominant spinocerebellar ataxias from clinical and genetic points of viewSemantic proximity Read ↗

Spinocerebellar ataxias: an updateSemantic proximity Read ↗

Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine DiseasesSemantic proximity Read ↗

[The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].Semantic proximity Read ↗

Therapeutic antisense oligonucleotides for movement disordersSemantic proximity Read ↗

Polyglutamine spinocerebellar ataxias - from genes to potential treatments.Semantic proximity Read ↗

The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.Semantic proximity Read ↗

Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.